Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $160.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target boosted by Cantor Fitzgerald from $155.00 to $160.00 in a research note released on Wednesday,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other equities analysts have also issued reports about the company. Royal Bank Of Canada upped their target price on Mirum Pharmaceuticals from $135.00 to $155.00 and gave the company an “outperform” rating in a report on Thursday, October 8th. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a report on Thursday, August 27th. Stifel Nicolaus boosted their price objective on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Weiss Ratings cut Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, October 22nd. Finally, HC Wainwright upped their price objective on Mirum Pharmaceuticals from $200.00 to $202.00 and gave the company a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $154.94.

Mirum Pharmaceuticals Stock Up 0.2%

Mirum Pharmaceuticals stock traded up $0.18 during midday trading on Wednesday, hitting $93.72. 722,713 shares of the stock were exchanged, compared to its average volume of 710,635. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The business’s 50-day moving average price is $89.29 and its 200-day moving average price is $98.46. The stock has a market capitalization of $6.09 billion, a price-to-earnings ratio of -6.06 and a beta of 0.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm had revenue of $185.72 million during the quarter, compared to analysts’ expectations of $178.07 million. During the same quarter last year, the business posted $0.05 EPS. The company’s quarterly revenue was up 39.6% on a year-over-year basis. On average, research analysts expect that Mirum Pharmaceuticals will post -1.47 EPS for the current fiscal year.

Insider Activity

In related news, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the sale, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president directly owned 1,274 shares in the company, valued at $127,400. This trade represents a 96.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 116,659 shares of company stock valued at $11,404,100 in the last three months. Company insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth $513,945,000. Emerald Advisers LLC increased its holdings in Mirum Pharmaceuticals by 8.2% in the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock worth $36,699,000 after acquiring an additional 30,129 shares during the last quarter. Man Group plc purchased a new stake in Mirum Pharmaceuticals in the 2nd quarter worth about $4,353,000. Jupiter Topco LLC bought a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at about $691,672,000. Finally, Rice Hall James & Associates LLC bought a new stake in Mirum Pharmaceuticals in the 2nd quarter valued at about $12,956,000.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.